About

Jellagen Pty Ltd is a Med-Tech business manufacturing next generation collagen products sourced from Jellyfish for application in 2D and 3D cell culture and medical devices. Jellagen’s research grade materials are commercialised with distributors supporting sales into the global cell culture and stem cell research markets. Jellagen’s collagen products offers the potential of in vitro to in vivo applications as well as batch to batch consistency offering advantages to research and medical applications. Jellagen products enable the researcher to optimise their study through providing an effective starting material for culturing cells which decrease downtime and allow for more effective representation of human model.

Jellagen is aiming to produce ISO13485 certified medical grade collagen products in 2017 for bulk OEM opportunities for medical devices and clinical applications. Jellagen also conducts in-house research and development of new collagen technologies to support fabrication of new medical devices offering new approaches to wound management and tissue engineering.

 

Team Collaborations
Andrew Mearns Spragg

Andrew Mearns Spragg, CEO

Professor Andrew Mearns Spragg is a marine biotechnology entrepreneur with over 10 years commercial experience in developing and growing a successful venture backed business. He grew his first company, Aquapharm whilst holding a Royal Society of Edinburgh (RSE) Enterprise Fellowship in biotechnology and grew this to a company of >20FTEs focused on the development of novel targeted treatments for cancer and drug resistant bacteria (antibiotics) from chemical scaffolds derived from marine microorganisms, an untapped source of natural product chemistry. Since 2005, Prof Spragg has successfully raised over £10M in equity finance and secured >£1.5M competitive grant funding from EU and UK sources. Prof Spragg brings an extensive international contact network across the finance, pharmaceutical, consumer care & IB sectors.
Galvin Mould

Galvin Mould, Chairman

Commercial and regulatory guidance is provided by JPL’s chairman Mr Galvin Mould who has over 30 years experience in the medical device sector. Galvin has extensive experience in medical devices and is a consultant specialising in IP and innovative technology commercialisation. Galvin spent 11 years with Orthofix International NV.
NEEM Biotech

NEEM Biotech

NEEM biotech is a biotechnology company specialising in biochemistry, drug discovery and the isolation of unique and novel natural compounds. We are presently working with NEEM to further improve our understanding of jellyfish collagens and discover new, novel compounds from jellyfish.

Visit site

Swansea University

Swansea University

We are working with Swansea University with the aim of developing new collagen-based products such as medical and wound healing devices. This collaboration allows for the accelerated development of new and innovative processes for manipulating collagen, such as electrospinning and micro carriers, to allow more features and uses of collagen to be exploited. The Centre for NanoHealth (CNH) at Swansea University is at the forefront of medical imaging, diagnosis and treatment. CNH offers access to over 50 academic staff from the Colleges of Medicine, Engineering and Science, Health Board (NHS) clinicians, and industry. CNH is a member of several global nanohealth networks. The Centre combines nanotechnology with medical science to provide opportunities to develop innovative solutions to the world’s challenge of detecting the onset of diseases at the earliest stage.

Visit site